Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pulmonology
Volume 2012, Article ID 146081, 5 pages
http://dx.doi.org/10.1155/2012/146081
Case Report

Development of Bullous Disease during Treatment of Pulmonary Marginal Zone B-Cell Lymphoma

1Department of Internal Medicine, Wayne State University School of Medicine, 4201 St. Antoine, UHC-2E, Detroit, MI 48201, USA
2Medical Service, John D. Dingell VAMC, Detroit, MI 48201, USA

Received 2 July 2012; Accepted 5 August 2012

Academic Editors: G. Hillerdal and H. Kobayashi

Copyright © 2012 S. Ansari et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Inagaki, J. K. C. Chan, J. W. M. Ng et al., “Primary thymic extranodal marginal-zone B-cell lymphoma of mucosa-associated lymphoid tissue type exhibits distinctive clinicopathological and molecular features,” American Journal of Pathology, vol. 160, no. 4, pp. 1435–1443, 2002. View at Google Scholar · View at Scopus
  2. J. Pijpe, G. W. Van Imhoff, A. Vissink et al., “Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren's syndrome and associated MALT lymphoma,” Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 958–960, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Stolte, E. Bayerdörffer, A. Morgner et al., “Helicobacter and gastric MALT lymphoma,” Gut, vol. 50, supplement 3, pp. 19–24, 2002. View at Google Scholar · View at Scopus
  4. P. Koch, F. Del Valle, W. E. Berdel et al., “Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the german multicenter study GIT NHL 01/92,” Journal of Clinical Oncology, vol. 19, no. 18, pp. 3861–3873, 2001. View at Google Scholar · View at Scopus
  5. L. J. King, S. P. G. Padley, A. C. Wotherspoon, and A. G. Nicholson, “Pulmonary MALT lymphoma: imaging findings in 24 cases,” European Radiology, vol. 10, no. 12, pp. 1932–1938, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Rosebeck, P. C. Lucas, and L. M. McAllister-Lucas, “Protease activity of the API2-MALT1 fusion oncoprotein in MALT lymphoma development and treatment,” Future Oncology, vol. 7, no. 5, pp. 613–617, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Satoh, T. Kobayashi, T. Misao et al., “CT assessment of subtypes of pulmonary emphysema in smokers,” Chest, vol. 120, no. 3, pp. 725–729, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. U. I. Ekeowa, B. Gooptu, D. Belorgey et al., “α1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies,” Clinical Science, vol. 116, no. 11-12, pp. 837–850, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. V. Jeebun and I. A. Forrest, “Sarcoidosis: an under-recognised cause for bullous lung disease?” European Respiratory Journal, vol. 34, no. 4, pp. 999–1001, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Ishibashi, H. Akamatsu, M. Sunamori, T. Ishibashi, and T. Iwata, “Nodular pulmonary amyloidosis with bullae; report of a case,” Kyobu Geka, vol. 55, no. 12, pp. 1069–1072, 2002 (Japanese). View at Google Scholar · View at Scopus
  11. C. S. King, A. B. Holley, and J. H. Sherner, “Severe bullous lung disease due to marginal-zone-lymphoma-associated amyloidosis,” Respiratory Care, vol. 53, no. 11, pp. 1495–1498, 2008. View at Google Scholar · View at Scopus
  12. J. Y. Kang, H. J. Park, K. Y. Lee et al., “Extranodal marginal zone lymphoma occurring along the trachea and central airway,” Yonsei Medical Journal, vol. 49, no. 5, pp. 860–863, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Nakajima, K. Yasufuku, Y. Sekine, S. Yoshida, and I. Yoshino, “Mucosa-associated lymphoid tissue lymphoma of the left mainstem bronchus,” The Annals of Thoracic Surgery, vol. 91, no. 4, pp. 1281–1283, 2011. View at Google Scholar · View at Scopus
  14. M. Colombat, M. Stern, O. Groussard et al., “Pulmonary cystic disorder related to light chain deposition disease,” American Journal of Respiratory and Critical Care Medicine, vol. 173, no. 7, pp. 777–780, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. F. J. Giles, M. P. Smith, and A. H. Goldstone, “Chlorambucil lung toxicity,” Acta Haematologica, vol. 83, no. 3, pp. 156–158, 1990. View at Google Scholar · View at Scopus
  16. B. Crestani, A. Jaccard, D. Israel-Biet, L. J. Couderc, J. Frija, and J. P. Clauvel -, “Chlorambucil-associated pneumonitis,” Chest, vol. 105, no. 2, pp. 634–636, 1994. View at Google Scholar · View at Scopus
  17. S. Pakhale, Y. Moltyaner, D. Chamberlain, and N. Lazar, “Rapidly progressive pulmonary fibrosis in a patient treated with danazol for idiopathic thrombocytopenic purpura,” Canadian Respiratory Journal, vol. 11, no. 1, pp. 55–57, 2004. View at Google Scholar · View at Scopus
  18. A. R. Tonelli and M. L. Brantly, “Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies,” Therapeutic Advances in Respiratory Disease, vol. 4, no. 5, pp. 289–312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. J. E. Gadek, J. D. Fulmer, and J. A. Gelfand, “Danazol-induced augmentation of serum α1-antitrypsin levels in individuals with marked deficiency of this antiprotease,” Journal of Clinical Investigation, vol. 66, no. 1, pp. 82–87, 1980. View at Google Scholar · View at Scopus
  20. A. S. Becher, “The effect of chlorambucil on proteases and esterases,” Archives Internationales de Pharmacodynamie et de Thérapie, vol. 162, no. 1, pp. 186–193, 1966. View at Google Scholar